Geron Corporation (Nasdaq: GERN) announced on November 3rd that the FDA)has removed the full clinical hold on their investigational new drug application for imetelstat. In addition, the FDA stated that Geron’s proposed clinical development plan for imetelstat that is focused on high-risk myeloid malignancies, such as myelofibrosis (MF), is acceptable. Click here to read the full release.
2014 FDA REMOVES CLINICAL HOLD ON GERON’S IMETELSTAT
MPNRF | April 29, 2021